Phase III Study on HMPL-523 for Treatment of ITP
NCT05029635
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
272
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
DRUG:
HMPL-523
DRUG:
Placebo
Sponsor
Hutchmed